Cemiplimab, approved by the US FDA between 2018 and 2021 for cutaneous squamous cell carcinoma, basal cell carcinoma and NSCLC with high PD‐L1 expression [232, 233], demonstrates distinct toxicity patterns. This evidence concerns the gene CD274 and basal cell carcinoma.